No Data
No Data
Shen Wan Hongyuan: The beauty market has entered a stage of steady development and is optimistic about the market space and performance transformation of key domestic brands
China's beauty market has left a decade of rapid growth and has entered a stage of steady development.
Haohai Biotechnology (06826): 526,400 A-share restricted shares will be listed and circulated on April 1
Haohai Biotechnology (06826) issued an announcement regarding the first grant of the 2021 A-share Restricted Stock Incentive Plan to the Ministry...
Haohai Biotech's hyaluronic acid is still a good business, but ophthalmology is more complicated
“Investor Network” Cai Jun's hyaluronic acid competition among the Three Musketeers of Medicine and Aesthetics is getting hotter and hotter. Recently, Haohai Biotech (688366.SH, hereinafter referred to as the “Company”) and Aimeike released their 2023 Annual Report. During the reporting period, the company's operating income and net profit attributable to shareholders of listed companies were 2,654 million yuan and 416 million yuan respectively, up 24.59% and 130.58% year-on-year respectively. In the same period, Aimeike's operating revenue and net profit attributable to shareholders of listed companies were 2.87 billion yuan and 1,858 billion yuan respectively, up 47.99% and 47.08% year-on-year respectively. It should be pointed out that doctors who love American customers
Haohai Biotechnology (06826) issued 526,400 A-shares under the Restricted Stock Incentive Plan
Haohai Biotechnology (06826) issued an announcement on March 26, 2024, based on restricted stocks in 2021...
Haohai Biotechnology (06826.HK) cancelled 3.296,500 repurchased shares on March 19
Gelonghui March 19 | Haohai Biotechnology (06826.HK) issued an announcement to cancel 3.296,500 repurchased shares on March 19, 2024.
Haohai Biotech: 679,300 restricted shares were vested
Haohai Biotechnology (06826) issued an announcement. On March 18, 2024, the company held the 21st meeting of the 5th board of directors to review the “Proposal on Granting Part 2 of the Company's 2021 A-share Restricted Stock Incentive Plan for the First Time to Meet the Eligibility Requirements”. According to the authorization of the company's first extraordinary general meeting of shareholders in 2022, the first A-share class shareholders' meeting in 2022, and the first H-share class shareholders' meeting in 2022, the board of directors believes that the vesting conditions stipulated in the company's 2021 A share restricted stock incentive plan for the first time to grant a second vesting period have been fulfilled, and the current number of attributable shares
No Data